1,132 results on '"Oxymorphone"'
Search Results
2. Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
Catalog
Books, media, physical & digital resources
3. In vivo photopharmacology with light-activated opioid drugs.
4. Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
5. Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain
6. Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
7. A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
8. Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning
9. Peripheral antinociceptive effects of a bifunctional μ and δ opioid receptor ligand in rat model of inflammatory bladder pain.
10. Oxymorphone
11. Assessing the risks of abuse of opioids in real-world data
12. Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
13. Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
14. Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children
15. Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects
16. A preliminary study of hydrocodone and hydromorphone to oxycodone ratios for distinguishing impurities from independent opioid use.
17. Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain
18. Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
19. Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.
20. Oxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural Human Immunodeficiency Virus Outbreak in US History.
21. Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions
22. Declines and regional variation in opioid distribution by U.S. hospitals.
23. Opioids
24. Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)
25. Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
26. Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
27. Understanding the Agent, Part III: Specific Drugs
28. Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans — pilot study outcomes.
29. Lumbar Stenosis Outcomes Research II (LUSTORII)
30. A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)
31. Opioids for the Treatment of Pain in the Rehabilitation Patient
32. Oxycodone for pain management in the latent phase of labour - A pragmatic trial.
33. Pharmacogenetics
34. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
35. Direct Chemiluminescence Determination of Oxymorphone Using Potassium Permanganate and Polyphosphoric Acid
36. Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
37. Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
38. Post-operative Efficacy and Safety Study
39. Open Label Assessment of Long-Term Safety and Utility
40. Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain
41. A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone
42. Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy
43. Rapid Extraction and Qualitative Screening of 30 Drugs in Oral Fluid at Concentrations Recommended for the Investigation of DUID Cases
44. Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model
45. A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database.
46. Oxycodone pharmacokinetics and fetal exposure after intravenous or epidural administration to the ewe.
47. Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone Levels
48. Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests
49. Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium/calmodulin-dependent protein kinase II signaling
50. Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans — pilot study outcomes
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.